TABLE 3.
Inhibition of TV replication by a plaque reduction assay with synthetic type A and B oligosaccharide conjugates as inhibitors
| Oligosaccharide conjugatea | PFU (avg) | 95% CIb | Plaque reduction (%)c |
|---|---|---|---|
| BSA | 21.5 | 17.4–25.6 | −2.4 |
| B-BSA | 14.5 | 13.2–15.8 | 31.0 |
| B-PAA | 20.3 | 16.4–24.1 | 3.6 |
| A3-BSA | 19.3 | 15.6–22.9 | 8.3 |
| A2-BSA | 17.5 | 13.2–21.8 | 16.7 |
| A-BSA | 17.8 | 13.7–21.8 | 15.5 |
| Control (TV only) | 21.0 |
a
A- and B-BSA, BSA-conjugated A and B trisaccharides; A2- and A3-BSA, BSA-conjugated A type 2 and 3 tetrasaccharides; B-PAA, polyacrylamide-conjugated B trisaccharide. The control wells were TV not mixed with any oligosaccharides.
b
95% CI, confidence interval at the 95% confidence level.
c
Plaque reduction was calculation based on plaque numbers in the test wells compared with that of the control wells.